论文部分内容阅读
目的:观察卡培他滨联合长春瑞宾对紫杉醇类和／或蒽环类耐药的晚期转移性乳腺癌的疗效及安全性。方法:对24例紫杉类和／或蒽环类耐药的、具有可测量病灶的晚期乳腺癌患者采用卡培他滨联合长春瑞宾进行治疗,21 d为1个周期,治疗2-6个周期。所有患者以往均接受过1种以上包括紫杉醇和／或多柔比星化疗方案的化疗。结果:24例患者中4例接受了2个周期化疗,5例完成3个周期化疗,12例完成4个周期的化疗,3例完成6个周期化疗。有效率(RR)为45．8％。不良反应14例。结论:卡培他滨联合长春瑞宾治疗晚期转移性乳腺癌的疗效确切且不良反应轻,有望成为紫杉醇类和／或蒽环类药物治疗失败的晚期转移性乳腺癌的理想方案。
Objective: To observe the curative effect and safety of capecitabine and vinorelbine on paclitaxel and / or anthracycline-resistant advanced metastatic breast cancer. METHODS: Twenty-four patients with advanced breast cancer who were resistant to taxanes and / or anthracyclines with measurable disease were treated with capecitabine plus vinorelbine for 21 days for one cycle of treatment 2-6 A cycle. All patients had previously received more than one type of chemotherapy including paclitaxel and / or doxorubicin chemotherapy. Results: Four of the 24 patients received 2 cycles of chemotherapy, 5 completed 3 cycles of chemotherapy, 12 completed 4 cycles of chemotherapy, and 3 completed 6 cycles of chemotherapy. The effective rate (RR) was 45.8%. Adverse reactions in 14 cases. CONCLUSIONS: Capecitabine and vinorelbine are effective in the treatment of advanced metastatic breast cancer and have low adverse reactions. They are expected to be the ideal regimen for advanced metastatic breast cancer with failed paclitaxel and / or anthracycline therapy.